interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development
EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).
The EU Clinical Trials Register currently displays
44346
clinical trials with a EudraCT protocol, of which
7374
are clinical trials conducted with subjects less than 18 years old.
The register also displays information on
18700
older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see
Frequently Asked Questions ).
Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
Full Title: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persi...
Medical condition: Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Disease:
Version
SOC Term
Classification Code
Term
Level
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10008342
Cervix carcinoma
PT
Population Age: Adults, Elderly
Gender: Female
Trial protocol:ES(Ongoing)FR(Trial now transitioned)NO(Trial now transitioned)SE(Trial now transitioned)DE(Trial now transitioned)IT(Trial now transitioned)
Trial results:(No results available)
EudraCT Number: 2019-004046-16
Sponsor Protocol Number: IMC-F106C-101
Start Date*: 2020-04-08
Sponsor Name:Immunocore Ltd.
Full Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Pos...
Medical condition: HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers. Study IMC-F106C-101 will enroll participants with advanced cancers, including unresectable or metastatic melanoma, ovarian ca...
Disease:
Version
SOC Term
Classification Code
Term
Level
21.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10061873
Non-small cell lung cancer
PT
21.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10025665
Malignant melanoma of skin stage unspecified
LLT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10042863
Synovial sarcoma
PT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10064467
Urothelial carcinoma
LLT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10075566
Triple negative breast cancer
PT
20.0
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
10046769
Uterine carcinoma
LLT
21.1
10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Subscribe to this Search
To subscribe to the RSS feed for this search click
here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options:
Number of Trials to download:
Download Content:
Download Format:
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
• EEA CTAs: Date study was authorised to proceed • Outside EU/EEA: Date study was submitted in EudraCT